Evidence map›Paper›PMID 35903861›Full record

ArticleThe Journal of international medical research2022

Changes in liver enzymes and association with prognosis in patients with COVID-19: a retrospective case-control study.

Farhad Shaveisi-Zadeh, Bahram Nikkho, Mohamaad Bagher Khadem Erfan, Amir Amiri, Ali Azizi, Nasrin Mansouri, Mitra Tarlan, Zahra Rostami-Far

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Farhad Shaveisi-ZadehClinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Bahram NikkhoDepartment of Pathology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Mohamaad Bagher Khadem ErfanDepartment of Parasitology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Amir AmiriClinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ali AziziDepartment of Community Medicine, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID https://orcid.org/0000-0002-7128-4181
Nasrin MansouriClinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID https://orcid.org/0000-0002-8716-0909
Mitra TarlanClinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Zahra Rostami-FarCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of medical science, Sanandaj, Iran.ORCID https://orcid.org/0000-0001-9680-6671
Kermanshah University of Medical Sciences · IRKurdistan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCOVID-19 has recently emerged as a serious threat to global health. This study examined the laboratory investigations of patients with COVID-19, with an emphasis on liver enzymes.

methodsThis retrospective, single-center study was performed on patients with COVID-19 who were admitted to Imam Reza Hospital, Iran from March 2020 to February 2021. Laboratory tests included a complete blood cell count, white blood cell (WBC) count, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio, and levels of aspartate aminotransferase, alanine aminotransferase (ALT), and alkaline phosphatase. Patient survival was among the outcome measures investigated in association with laboratory findings.

resultsWe enrolled 77 patients with COVID-19 and 63 healthy controls. In comparison with the control group, patients with COVID-19 showed COVID-19 increased ALT, WBC, neutrophils, NLR, and PLR, and decreased platelet counts and lymphocytes.

conclusionAlthough elevated levels of AST, NLR, PLR, and LMR were found in patients with COVID-19, they were not linked to mortality. Given the presence of AST in other tissues, the influence of SARS-CoV-2 on the liver should be interpreted with caution.

Indexed as

COVID-19Blood PlateletsCase-Control StudiesHumansLiverLymphocytesNeutrophilsPrognosisRetrospective StudiesSARS-CoV-2case–control studyCOVID-19liver diseaseliver enzymeliver injurySARS-CoV-2

Identifiers

PMID35903861
PMCPMC9340912
OpenAlexW4288740332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.